USFDA issues Form-483 with 10 observations to Lupins Pithampur plant
In November last year, USFDA had issued Form-483 with eight observations each for product and raw material production centres at Lupins Mandideep-based manufacturing facility.
The US Food and Drug Administration (USFDA) inspected the plant from March 21 to March 29, 2023.
The inspection closed with the issuance of a Form-483 with ten observations, Lupin said in a regulatory filing.
"We are addressing the observations comprehensively and will work with the US FDA to resolve these issues at the earliest," it added.
As per the USFDA, Form 483 is issued to a firm's management at the conclusion of an inspection when the investigator has observed any conditions that in its judgement may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.
In November last year, USFDA had issued Form-483 with eight observations each for product and raw material production centres at Lupin's Mandideep-based manufacturing facility.
In October 2022, the drugmaker announced that the US health regulator has issued Form-483 with five observations following a pre-approval inspection of its Unit-2 injectable manufacturing facility at Nagpur.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.